Log in

NASDAQ:DMAC - DiaMedica Therapeutics Stock Price, Forecast & News

$2.95
+0.13 (+4.61 %)
(As of 12/10/2019 09:25 AM ET)
Today's Range
$2.73
Now: $2.95
$2.97
50-Day Range
$2.62
MA: $3.11
$3.72
52-Week Range
$1.70
Now: $2.95
$5.93
Volume70,047 shs
Average Volume39,525 shs
Market Capitalization$35.28 million
P/E RatioN/A
Dividend YieldN/A
Beta2.89
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMAC
CUSIPN/A
CIKN/A
Phone763-312-6755

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$1.43 per share

Profitability

Net Income$-5,730,000.00

Miscellaneous

Employees9
Market Cap$35.28 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.


DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc (NASDAQ:DMAC) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. View DiaMedica Therapeutics' Earnings History.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for DiaMedica Therapeutics.

What price target have analysts set for DMAC?

3 brokers have issued 12 month price objectives for DiaMedica Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they expect DiaMedica Therapeutics' share price to reach $9.33 in the next twelve months. This suggests a possible upside of 216.4% from the stock's current price. View Analyst Price Targets for DiaMedica Therapeutics.

What is the consensus analysts' recommendation for DiaMedica Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DiaMedica Therapeutics.

Has DiaMedica Therapeutics been receiving favorable news coverage?

Media headlines about DMAC stock have been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a news impact score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for DiaMedica Therapeutics.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totalling 34,000 shares, an increase of 771.8% from the October 31st total of 3,900 shares. Based on an average daily trading volume, of 45,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.4% of the company's shares are sold short. View DiaMedica Therapeutics' Current Options Chain.

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Capricor Therapeutics (CAPR), Inovio Pharmaceuticals (INO), Datasea (DTSS), Adamis Pharmaceuticals (ADMP), Alector (ALEC), Andersons (ANDE), Arcturus Therapeutics (ARCT) and AzurRx BioPharma (AZRX).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the folowing people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 57)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.59%) and Commonwealth Equity Services LLC (0.11%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View Institutional Ownership Trends for DiaMedica Therapeutics.

Which major investors are buying DiaMedica Therapeutics stock?

DMAC stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC and Commonwealth Equity Services LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View Insider Buying and Selling for DiaMedica Therapeutics.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $2.95.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $35.28 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 9 workers across the globe.View Additional Information About DiaMedica Therapeutics.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]


MarketBeat Community Rating for DiaMedica Therapeutics (NASDAQ DMAC)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Preferred Stock

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel